A 20-year-old warning just got turned on its head
For two decades, the standard advice to women was blunt: do not take menopausal hormone therapy to protect your memory, and it might even raise your dementia risk. A new study from Stanford Medicine, published in the journal Neurology, looked at the one piece of evidence almost nobody had examined at scale, the actual brains of women after death, and found the opposite signal.
Women who had used estrogen-only hormone therapy had roughly 35 percent lower odds of carrying the defining physical hallmarks of Alzheimer’s disease in their brains. That is a striking reversal of the received wisdom. It is also, on close reading, a carefully bounded finding with a very specific fine print, and the fine print is the whole story. Here is what the study actually shows, and what it does not.
| What the study found | What it means for you |
|---|---|
| 35% lower odds of Alzheimer’s brain hallmarks | A real, measurable difference, but an association, not proof of cause. |
| 39% lower odds of a dementia diagnosis in life | The brain evidence and the clinical evidence pointed the same way. |
| Benefit seen only for estrogen-only pills | Does not apply to combined therapy or to skin patches and gels. |
| Effect called “modest but meaningful” | Real and consistent, but far weaker than age or the APOE4 gene. |
| It is an association, not causation | This reopens a conversation, it does not settle it. |
Why looking at brains matters
Most studies of hormones and dementia rely on clinical diagnoses, which the researchers point out are often imprecise. Many conditions cloud memory, from a stroke to a bad night’s sleep, and a doctor’s label of “dementia” does not tell you what is physically happening inside the skull.
This study went to the source. The Stanford team, led by senior author Hadi Hosseini and co-authors Jennifer Bruno and Jacob Shaw, drew on two existing research databases totaling 21,462 participants. They focused on deceased women whose brains had been autopsied and examined for two defining features of Alzheimer’s disease: amyloid plaques and neurofibrillary tangles, plus a third measure, the density of individual plaques.
They compared 258 brains of women who had reported using estrogen-only hormone therapy against roughly 2,701 brains of women who had used no hormone therapy at all. As Hosseini put it, this is the gold-standard outcome, and nobody had previously examined it in substantial numbers. That autopsy grounding is what makes the finding hard to wave away.
The two numbers, and why they agree
Two results came out of the work, and the fact that they line up is what gives the study weight.
In the autopsied brains, estrogen-only users had about 35 percent lower odds of Alzheimer’s pathology. Separately, among living participants whose spinal fluid and blood were analyzed, estrogen-only users had 39 percent lower odds of ever receiving a clinical dementia diagnosis, and they did better on memory tests and on their ability to live independently. When the physical brain evidence and the real-world clinical evidence point in the same direction, a finding is harder to dismiss as a fluke.
Crucially, the team adjusted for the heavy hitters: the APOE4 gene variant, high blood pressure, age, education and race. The effect survived all of that. Bruno called it “modest but meaningful and statistically significant,” while being careful to add that it is nowhere near as powerful as age or APOE4. What impressed the researchers was its consistency across several different Alzheimer’s measures.
The fine print that changes everything
Now the catch, and it is a big one. This benefit applies to one narrow slice of hormone therapy only.
It was seen for estrogen-only therapy taken as a pill. Estrogen-only regimens are generally prescribed to women who have had a hysterectomy and no longer have a uterus, which by age 60 is more than 30 percent of women. The study could not draw any conclusion about the combined estrogen-plus-progestin formulation, because too few autopsied women had used it. And it did not cover topical estrogen delivered through the skin as a patch or gel, only the oral form. So the headline cannot be stretched to “hormone therapy protects the brain.” The honest version is narrower and more specific than that.
There is also the matter of causation. This is an observational association. It is entirely possible that women who took estrogen-only therapy differed from non-users in ways the study could not measure, and that some of those differences, rather than the estrogen itself, explain the gap. The researchers say so plainly: the link is clear, but it is not definitive proof of cause and effect.
The honest gaps
A few things are worth holding in mind before anyone treats this as settled.
The study is observational, so it can show a pattern but not prove the therapy caused it. It speaks only to oral estrogen-only therapy, leaving the most commonly discussed combined formulation an open question. The women studied were older, average age around 70, and many started therapy late; the authors argue this means they may have underestimated the benefit, since other recent evidence suggests hormone therapy helps most when started during or soon after menopause, but that is an inference, not a measured result. And a single study, however well designed, does not overturn 20 years of guidance on its own. It invites the next study rather than closing the book.
It is also fair to note the whiplash women have been handed. The 2003 Women’s Health Initiative Memory Study tied the combined formulation to higher dementia, breast cancer and heart risk, and hormone therapy use fell from a lifetime rate near 27 percent to below 5 percent today. In 2025 the FDA removed a black-box warning tied to that era. Now this. For anyone trying to make a personal decision, the ground has moved repeatedly, which is exactly why the next section matters.
What to do with this if menopause is on your mind
This is genuinely useful to know, but it is not a reason to act alone.
- Do not start hormone therapy on the basis of this study. It is one observational finding about one specific formulation, not a treatment recommendation.
- Know which formulation the finding covers. The signal was for oral estrogen-only therapy, the kind generally used after a hysterectomy, not for combined therapy or skin patches.
- Bring your full history to the conversation. Whether hormone therapy makes sense depends on your age, your heart and breast cancer risk, and whether you still have a uterus. That is a clinician’s call, not a headline’s.
- Ask about timing. Emerging evidence suggests hormone therapy behaves differently depending on how soon after menopause it is started. If you are weighing it, that timing question is worth raising.
The real significance here is not that a pill was proven to prevent Alzheimer’s, because it was not. It is that researchers finally looked at the hard physical evidence, the brains themselves, and found a consistent signal pointing the opposite way from 20 years of caution, at least for one formulation. As one of the authors put it, the long-standing advice was to avoid hormone therapy for memory. This study, she said, flies in the face of that. It does not end the debate. It reopens it, honestly and with better evidence than before.